Advertisement
MRK vs NVS
Which Stock Would AI Choose? Merck & Co. (MRK) vs. Novartis AG (NVS) Stock Comparison
Key Takeaways
- NVS shows stronger year-to-date performance at 7.11% compared to MRK's 5.50%, reflecting positive momentum from recent regulatory approvals.
- Both stocks have experienced pullbacks in recent weeks, with MRK declining around 7% over the past month versus NVS's approximately 4% drop.
- NVS trades at a lower forward P/E ratio (price-to-earnings ratio) of 16.03, suggesting better relative valuation than MRK's 21.55.
- MRK offers a lower beta of 0.28, indicating greater price stability amid market volatility compared to NVS's 0.52.
- Recent catalysts include NVS's strong Q1 results and new drug approvals, while MRK approaches its upcoming quarterly earnings.
Introduction
Merck & Co. (MRK) and Novartis AG (NVS) are leading pharmaceutical giants with robust portfolios in oncology, immunology, and innovative therapies. This comparison analyzes their recent market performance, valuation metrics, and key developments amid a dynamic healthcare sector. Traders seeking short-term momentum and long-term investors focused on dividend stability or growth catalysts will find value in understanding their relative positioning, especially as both navigate patent cliffs, regulatory wins, and macroeconomic pressures in the current environment.
MRK Overview and Recent Performance
Merck & Co. (MRK), a global leader in pharmaceuticals, derives significant revenue from blockbuster drugs like Keytruda for cancer treatment. In recent market activity, shares have traded around $110, down from late-March levels near $120, reflecting a roughly 7% monthly decline amid broader sector rotation. The stock's low beta of 0.28 underscores its defensive nature, with a market cap of $272 billion and a dividend yield of 3.08% appealing to income-focused holders. Sentiment has been tempered by anticipation of Q1 earnings on April 30, where analysts project $15.9 billion in revenue, alongside health awareness initiatives boosting visibility.
NVS Overview and Recent Performance
Novartis AG (NVS), headquartered in Switzerland and listed as an ADR, focuses on innovative medicines across cardiovascular, neuroscience, and immunology areas. Shares recently hovered near $144, pulling back about 4% over the past month from March highs around $152, yet outperforming peers in stability. With a $278 billion market cap, forward P/E of 16.03, and 3.29% dividend yield, it presents attractive valuation. Recent weeks saw positive sentiment from strong Q1 growth in priority brands, reaffirmed full-year guidance, and regulatory nods for Rhapsido in urticaria treatment, an SMA drug, and a malaria therapy.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI-driven trading bots, selected from hundreds available—specifically 25 best out of 351 total bots—that adapt to current market conditions across thousands of tickers. These bots employ diverse strategies like swing trading, day trading, and pattern recognition, with varying timeframes from intraday to longer holds. Performance highlights include win rates often in the 60-80% range for top performers, profit factors exceeding 1.5, and annualized returns up to 50% or more in backtests and live trading, depending on risk settings. Whether focusing on pharma stocks like MRK or NVS, or broader markets, these curated tools offer data-backed signals for traders. Explore the page to identify bots matching your style.
Head-to-Head Comparison
Both MRK and NVS operate in the pharmaceuticals sector, but MRK leans heavily on oncology blockbusters, exposing it to patent expiration risks, while NVS diversifies across more therapeutic areas for balanced growth. Recent momentum favors NVS with YTD gains and approvals driving sentiment, versus MRK's earnings anticipation amid pullbacks. Valuation edges to NVS on lower forward P/E, though MRK counters with superior stability (lower beta) and comparable dividends. Risk factors include generic competition for both, but NVS's international exposure adds currency volatility trade-offs.
Tickeron AI Verdict
Tickeron’s AI currently leans toward NVS based on trend consistency from regulatory catalysts, reaffirmed guidance, and relative valuation strength, positioning it better for near-term upside probability amid recent healthcare sector dynamics. MRK remains a solid defensive play, particularly post-earnings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRK is a Buy and NVS is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MRK’s FA Score shows that 3 FA rating(s) are green whileNVS’s FA Score has 3 green FA rating(s).
- MRK’s FA Score: 3 green, 2 red.
- NVS’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MRK’s TA Score shows that 6 TA indicator(s) are bullish while NVS’s TA Score has 7 bullish TA indicator(s).
- MRK’s TA Score: 6 bullish, 4 bearish.
- NVS’s TA Score: 7 bullish, 2 bearish.
Price Growth
MRK (@Pharmaceuticals: Major) experienced а +3.28% price change this week, while NVS (@Pharmaceuticals: Major) price change was +3.08% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.69%. For the same industry, the average monthly price growth was +14.25%, and the average quarterly price growth was +7.16%.
Reported Earning Dates
MRK is expected to report earnings on Aug 04, 2026.
NVS is expected to report earnings on Jul 21, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.69% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| MRK | NVS | MRK / NVS | |
| Capitalization | 320B | 302B | 106% |
| EBITDA | 19.4B | 22.4B | 87% |
| Gain YTD | 24.889 | 19.484 | 128% |
| P/E Ratio | 32.53 | 21.34 | 152% |
| Revenue | 65.8B | 56.6B | 116% |
| Total Cash | N/A | 6.98B | - |
| Total Debt | 49.1B | 47B | 104% |
MRK | NVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 14 Undervalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 41 | 5 | |
SMR RATING 1..100 | 47 | 27 | |
PRICE GROWTH RATING 1..100 | 12 | 45 | |
P/E GROWTH RATING 1..100 | 6 | 37 | |
SEASONALITY SCORE 1..100 | 47 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVS's Valuation (10) in the Pharmaceuticals Major industry is in the same range as MRK (14). This means that NVS’s stock grew similarly to MRK’s over the last 12 months.
NVS's Profit vs Risk Rating (5) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (41). This means that NVS’s stock grew somewhat faster than MRK’s over the last 12 months.
NVS's SMR Rating (27) in the Pharmaceuticals Major industry is in the same range as MRK (47). This means that NVS’s stock grew similarly to MRK’s over the last 12 months.
MRK's Price Growth Rating (12) in the Pharmaceuticals Major industry is somewhat better than the same rating for NVS (45). This means that MRK’s stock grew somewhat faster than NVS’s over the last 12 months.
MRK's P/E Growth Rating (6) in the Pharmaceuticals Major industry is in the same range as NVS (37). This means that MRK’s stock grew similarly to NVS’s over the last 12 months.
| MRK | NVS | |
|---|---|---|
| RSI ODDS (%) | 5 days ago 51% | N/A |
| Stochastic ODDS (%) | 5 days ago 63% | 5 days ago 44% |
| Momentum ODDS (%) | 5 days ago 56% | 5 days ago 46% |
| MACD ODDS (%) | 5 days ago 52% | 5 days ago 53% |
| TrendWeek ODDS (%) | 5 days ago 55% | 5 days ago 52% |
| TrendMonth ODDS (%) | 5 days ago 54% | 5 days ago 49% |
| Advances ODDS (%) | 8 days ago 54% | 8 days ago 51% |
| Declines ODDS (%) | 6 days ago 51% | 6 days ago 46% |
| BollingerBands ODDS (%) | 5 days ago 57% | 5 days ago 50% |
| Aroon ODDS (%) | 5 days ago 64% | 5 days ago 50% |
Advertisement